Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

ClinicalTrials.gov ID: NCT01549834

Public ClinicalTrials.gov record NCT01549834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Study identification

NCT ID
NCT01549834
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
434 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
55 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2012
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013
Last update posted
Oct 30, 2014

2012 – 2013

United States locations

U.S. sites
11
U.S. states
6
U.S. cities
11
Facility City State ZIP Site status
Site Reference ID/Investigator# 66528 Fresno California 93720
Site Reference ID/Investigator# 69602 Long Beach California 90806
Site Reference ID/Investigator# 66527 San Francisco California 94109-4841
Site Reference ID/Investigator# 66530 Hamden Connecticut 06518
Site Reference ID/Investigator# 66522 Delray Beach Florida 33445
Site Reference ID/Investigator# 66524 Orlando Florida 32806
Site Reference ID/Investigator# 66531 Tampa Florida 33613
Site Reference ID/Investigator# 66529 West Palm Beach Florida 33407
Site Reference ID/Investigator# 66526 Elk Grove Village Illinois 60007
Site Reference ID/Investigator# 66525 Staten Island New York 10312
Site Reference ID/Investigator# 66523 Bennington Vermont 05201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01549834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2014 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01549834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →